On the 30 September 2026 Flerie AB's Net Asset Value (NAV) was SEK 3,113 million and NAV per share was SEK 35.91. Return on NAV per share in the month was -6.8%.
| Allocation of NAV | Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
| Product Development | ||||
| Lipum | 100% | 348 | 4.01 | 11.2% |
| Prokarium | 50% | 296 | 3.41 | 9.5% |
| Atrogi | 47% | 215 | 2.48 | 6.9% |
| KAHR Medical | 34% | 214 | 2.47 | 6.9% |
| Microbiotica | 10% | 191 | 2.20 | 6.1% |
| Bonsai Biotherapeutics | 100% | 158 | 1.82 | 5.1% |
| AnaCardio | 9% | 105 | 1.22 | 3.4% |
| Mendus | 22% | 89 | 1.03 | 2.9% |
| Xintela | 60% | 88 | 1.02 | 2.8% |
| Xspray Pharma | 17% | 85 | 0.98 | 2.7% |
| Geneos Therapeutics | 12% | 71 | 0.82 | 2.3% |
| EpiEndo Pharmaceuticals | 9% | 56 | 0.65 | 1.8% |
| Vitara Biomedical | 9% | 51 | 0.58 | 1.6% |
| Egetis Therapeutics | 1% | 43 | 0.50 | 1.4% |
| Buzzard Pharmaceuticals | 15% | 33 | 0.38 | 1.1% |
| Amarna Therapeutics | 58% | 11 | 0.13 | 0.4% |
| Strike Pharma | 18% | 11 | 0.12 | 0.3% |
| Empros Pharma | 79% | 0 | 0.00 | 0.0% |
| Total | 2,065 | 23.82 | 66.3% | |
| Commercial Growth | ||||
| Symcel | 30% | 211 | 2.43 | 6.8% |
| NorthX Biologics | 61% | 202 | 2.33 | 6.5% |
| Chromafora | 29% | 149 | 1.72 | 4.8% |
| Nanologica | 50% | 50 | 0.58 | 1.6% |
| Frontier Biosolutions | 2% | 27 | 0.31 | 0.9% |
| Bohus Biotech | 45% | 22 | 0.26 | 0.7% |
| Total | 661 | 7.63 | 21.2% | |
| Assets and liabilities related to Portfolio companies | 131 | 1.51 | 4.2% | |
| Other assets and liabilities | 256 | 2.95 | 8.2% | |
| Net Asset Value | 3,113 | 35.91 | 100.0% | |
For more information:
Ted Fjällman, CEO
Email: ir@flerie.com
Flerie in brief
Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com